MyMD Pharmaceuticals, Akers Biosciences Merging to Form Baltimore-Based Company
A merger of two medical device companies is bringing about a new Baltimore-based company that will be listed on the Nasdaq. MyMD Pharmaceuticals, Inc. has entered into a deal to merge with Akers Biosciences, Inc. to form a combined company focused on developing the drug candidates in MyMD Pharmaceuticals’ pipeline that use immunotherapy to treat autoimmune and age-related diseases. Dr. Adam Kaplin, an assistant professor at the The Johns Hopkins University School of Medicine in Baltimore, will become chief scientific officer of the company, according to Technical.ly.